CN103787949A - Compound for protecting transplanted organs and application thereof - Google Patents
Compound for protecting transplanted organs and application thereof Download PDFInfo
- Publication number
- CN103787949A CN103787949A CN201310524006.4A CN201310524006A CN103787949A CN 103787949 A CN103787949 A CN 103787949A CN 201310524006 A CN201310524006 A CN 201310524006A CN 103787949 A CN103787949 A CN 103787949A
- Authority
- CN
- China
- Prior art keywords
- compound
- organ
- medicine
- preparation
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 210000000056 organ Anatomy 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 36
- 238000002054 transplantation Methods 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 12
- 206010052779 Transplant rejections Diseases 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 229930105110 Cyclosporin A Natural products 0.000 description 5
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013618 particulate matter Substances 0.000 description 3
- -1 phosphatide Chemical compound 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a compound as well as a drug composition and new application thereof. The compound is applied to drugs for protecting transplanted organs. The compound can relieve symptoms of rejection reaction and can effectively inhibit rejection reaction after organ transplantation. Animal experiments prove that the compound disclosed by the invention has a very obvious effect on protecting the transplanted organs and can effectively improve the living conditions of animals receiving organ transplantation.
Description
Technical field
The present invention relates to compound and pharmacologically acceptable salt and its analogue of a class protection transplant organ; the pharmaceutical composition of being prepared by above-claimed cpd and pharmacologically acceptable salt thereof and its analogue, and described compound or pharmaceutically acceptable salt thereof and analogue thereof suppress the purposes in the medicine of organ transplant rejection in preparation.
Background technology
Organ transplantation is a kind of very important treatment means,, being described as the great life science progress that changes human lives 20th century, China has totally successfully carried out organ transplantation 110,000 examples at present, be the second largest organ transplantation state that is only second to the U.S., transplant number and maintain the leading position.Legal and illegal organ transplantation conservative estimation in worldwide, totally carries out examples up to a million.And after organ transplantation, sixty-four dollar question is exactly the acute or long-standing immunological rejection of short-term.
At present in the treatment of the rejection for inhibition organ transplantation, main employing pharmacological agent, main drug application is Ciclosporin A clinically, this effect of drugs is single, the immunologic rejection reaction that is mainly used in kidney, liver, the heart, lung, bone marrow transplantation is upper, but obtains exactissima diligentia using dosage when its untoward reaction in cardiovascular, kidney and central nervous system makes it in application; Tacrolimus and sirolimus are macrolide immunosuppressants, its immunosuppressive effect is 10-100 times of ciclosporin, but macrolide immunosuppressants can cause the illnesss such as renal dysfunction, hypertension, hyperglycemia, leukocytosis and high potassium hypomagnesemia; DNA synthetic inhibitor, as azathioprine, mycophenlate mofetil texts, and can cause the side effects such as gastrointestinal reaction, blood system obstacle, oligoleukocythemia, dysfunction of liver; Report that in addition trypterygine, Schuttgelb etc. are at the report of the provide protection of organ transplantation, but in general, many medicines of the whole provide protection for organ transplantation, effect all can not be satisfactory.
The inventor is surprised to find that one group of compound and similar compound or its pharmacologically acceptable salt thereof have an unexpected effect on the medicine of preparation inhibition organ transplant rejection, suppress organ transplant rejection for this compounds at present and there is no report.
Summary of the invention
The invention provides one group of compound and similar compound thereof or its pharmacologically acceptable salt new purposes in the medicine of preparation inhibition organ transplant rejection.
Technical scheme of the present invention is as follows:
The invention provides one group of compound or pharmaceutically acceptable salt thereof that can suppress organ transplant rejection disease, and analogue, the structure of described compound is as follows:
compound (B);
Above formula compound and analogue thereof or its pharmacologically acceptable salt can be prepared into through topical, the various preparations of gastrointestinal administration or parenteral administration.Described preparation comprises ordinary preparation, controlled release preparation, targeting preparation etc.Described local administration preparation is through the powder injection of organ administration, aqueous injection, microball preparation, nanometer formulation, Liposomal formulation, dendrimer preparation, polyethyleneglycol modified preparation, aqueogel etc.Described parenteral administration preparation is the formulation of suitable intravenous injection, intramuscular injection, subcutaneous injection, bone marrow injection, transdermal administration, mucosa delivery and inhalation.
The inventor studies discovery: this compounds can greatly be alleviated inhibition organ transplant rejection symptom, and from the result of pharmacodynamic experiment, the effect of the inhibition rejection of this compounds exceeds the medicine of current clinical application.The exploitation of this new compound is by for to play very large effect to the recovery of following Organ Transplantation Patients.For removing sufferer misery, the quality of life that improves patient is significant.
Accompanying drawing explanation
fig. 1mouse liver transplantation Histopathological Studies result, is followed successively by Ciclosporin A, medicine A, medicine B, medicine C
Embodiment
The present invention's compound used can be purchased, and also can be prepared according to disclosed preparation method, and it does not limit the scope of the invention.
medicine Preparation Example
compound (B);
compound (C).
Preparation containing compd A lyophilized injection:
1. altogether 50mg and 900mg formula (A) compound mix and make it dissolving in water for injection to get N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer;
2. after mixing dissolving, after stable, first use 0.45um millipore filtration coarse filtration, then use 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other lyophilized vaccines and auxiliary material;
4. carry out procedural freeze-drying;
5. carry out the corresponding inspections such as pyrogen, aseptic, visible foreign matters, particulate matter, stand-by after all meeting the requirements.
Preparation containing compd B lyophilized injection:
1. altogether 50mg and 900mg formula (B) compound mix and make it dissolving in water for injection to get N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer;
2. after mixing dissolving, after stable, first use 0.45um millipore filtration coarse filtration, then use 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other lyophilized vaccines and auxiliary material;
4. carry out procedural freeze-drying;
5. carry out the corresponding inspections such as pyrogen, aseptic, visible foreign matters, particulate matter, stand-by after all meeting the requirements.
Preparation containing the dry injection of Compound C:
1. altogether 50mg and 900mg formula (C) compound mix and make it dissolving in water for injection to get N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer;
2. after mixing dissolving, after stable, first use 0.45um millipore filtration coarse filtration, then use 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other lyophilized vaccines and auxiliary material;
4. carry out procedural freeze-drying;
5. carry out the corresponding inspections such as pyrogen, aseptic, visible foreign matters, particulate matter, stand-by after all meeting the requirements.
effect embodiment:
1 provide protection of medicine A-C to mouse transplant organ
1.1 laboratory animal and grouping
Adopt the clean level of healthy adult rat, male, body weight 200-300g.Raising condition meets SPF standard.Acceptor body weight is slightly larger than donor.Preoperative fasting, adopts chlorine peace ketone 75mg/kg intraperitoneal injection of anesthesia, under operating microscope, operates.According to Meng Kewei, the method that the mad expert of grade of Lee ancestor successively reports is carried out rat orthotopic liver transplantation.Method referring to the foundation of the orthotopic liver transplantation model of the 18th the 1st phase of volume in 2004 of Chinese Reconstructive surgery magazine and art formula is improved and the Schuttgelb of the 13rd the 5th phase of volume in 2009 of Chinese Tissue Engineering Study and clinical rehabilitation on Rat Liver Transplantation after the impact of hepatocellular apoptosis in acute rejection.Establish after model, 100 animal models that delivery type is successfully prepared are by being divided at random 5 groups, 20 every group.After transplanting, within the 1st day, start to carry out intraperitoneal injection by echelon design, model control group only gives physiological saline, medicine A group gives medicine A 0.5mg/(kgd), medicine B group gives medicine B 0.5mg/(kgd), medicine C group gives medicine C 0.5mg/(kgd), contrast medicine Ciclosporin A group gives Ciclosporin A 3 mg/(kgd).After transplanting, within the 7th day, get blood, and put to death at random 8 rats in each group, get the micro-Microscopic observation pathologic condition of liver specimens, remaining rat continues the breeding observing survival time.
1.2 testing index
Observe and record each group of mouse operation survival rate, survival time.Get and transplant latter the 7th day each group execution rat liver sample, carry out hematoxylin-eosin staining, under mirror, observe, detect the situation of transaminase in blood (ALT) simultaneously.
1.3 statistical analysis
Each group rat is observed the data obtained with mean ± standard deviation (x ± s) represent.Between group, carry out t check.
1.4 experimental result
1.4.1 medicine is on suppressing the impact of organ transplant rejection
Model group is due to organ transplant rejection, and liver is affected, and function reduces, so ALT level significantly raises; With model group comparison, medicine A-C all can significantly reduce ALT level (P<0.01), and action effect be far better than contrast ciclosporin group (P<0.01), refer to table 1.
Table 1 different dosing group is on suppressing the impact of ALT in organ transplant rejection rat serum
| Group | ALT ( IU /L ) |
| Model group | 1050.5±170.4 |
| Medicine A group | 200.1±33.5** |
| Medicine B group | 202.5±23.8** |
| Medicine C group | 190.7±51.2** |
| Ciclosporin A | 488.66±90.2* |
With relatively * P<0.05**P<0.01 of model group
1.4.2 the comparison of survival time after mouse organ transplantation
The survival time of medicine A-C group is obviously longer than model group and positive drug ciclosporin control group, and effect significantly.Refer to table 2.
The contrast of table 2 survival of rats time
| Group | Survival time (my god) |
| Model group | 7.1±1.3 |
| Medicine A group | 30.6±5.0** |
| Medicine B group | 34.1±3.6** |
| Medicine C group | 31.1±2.7** |
| Ciclosporin A | 10.4±2.9* |
With relatively * P<0.05**P<0.01 of model group
1.4.3 histological observation result:
The histological observation result of liver, medicine A, B, C group is significantly better than model group and positive drug ciclosporin control group, and effect is significantly.Refer to Fig. 1.
Comprehensive above-mentioned experimental result is reached a conclusion: compound (A), and (B), the medicine of (C) preparing all can obviously improve the rejection symptom of organ transplantation, plays the provide protection to transplant organ preferably, and its action effect is significantly better than current clinical application.
Claims (8)
1. a class can be protected the compound or pharmaceutically acceptable salt thereof of transplant organ, and analogue, and the structure of described compound is as follows:
Compound (A);
compound (B);
Compound (C).
2. a pharmaceutical composition, it comprises compound claimed in claim 1 and pharmacologically acceptable salt and its analogue.
3. the pharmaceutical composition of claim 2, it can be ordinary preparation, controlled release preparation, targeting preparation etc.
4. the pharmaceutical composition of claim 2, described compound and pharmacologically acceptable salt thereof and its analogue are prepared into through topical, the various preparations of gastrointestinal administration or parenteral administration.
5. topical described in claim 4, for being directly administered into the various preparations of organ.
6. compound and pharmacologically acceptable salt thereof and its analogue purposes in the medicine of preparation protection transplant organ described in claim 2.
7. compound and pharmacologically acceptable salt thereof and its analogue purposes in the medicine of preparation inhibition organ transplant rejection described in claim 2.
8. the purposes of claim 7, the inhibition organ transplant rejection described in it comprises rejection or the relative disease that the various organ transplantations except head produce.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310524006.4A CN103787949A (en) | 2012-10-31 | 2013-10-30 | Compound for protecting transplanted organs and application thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210437672.X | 2012-10-31 | ||
| CN201210437672 | 2012-10-31 | ||
| CN201310524006.4A CN103787949A (en) | 2012-10-31 | 2013-10-30 | Compound for protecting transplanted organs and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103787949A true CN103787949A (en) | 2014-05-14 |
Family
ID=50664061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310524006.4A Pending CN103787949A (en) | 2012-10-31 | 2013-10-30 | Compound for protecting transplanted organs and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103787949A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090286789A1 (en) * | 2005-11-01 | 2009-11-19 | Targegen, Inc. | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases |
| US20100311985A1 (en) * | 2007-12-03 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Indolinone derivatives and process for their manufacture |
-
2013
- 2013-10-30 CN CN201310524006.4A patent/CN103787949A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090286789A1 (en) * | 2005-11-01 | 2009-11-19 | Targegen, Inc. | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases |
| US20100311985A1 (en) * | 2007-12-03 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Indolinone derivatives and process for their manufacture |
Non-Patent Citations (1)
| Title |
|---|
| WILLIAM R. ANTONIOS-MCCREA等: "LHMDS mediated tandem acylation–cyclization of 2-aminobenzenecarbonitriles with 2-benzymidazol-2-yl acetates: a short and efficient route to the synthesis of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones", 《TETRAHEDRON LETTERS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease | |
| Zhou et al. | Shape regulated anticancer activities and systematic toxicities of drug nanocrystals in vivo | |
| KR101563308B1 (en) | Inclusion complexes of pinocembrin with cyclodextrin or its derivatives | |
| CN105263475A (en) | Intravenous emulsions of triptolide as immunomodulators and anticancer agents | |
| ES2393792T3 (en) | Pharmaceutical composition to treat nephropathy and healthy food comprising herbal extracts | |
| CN104628657A (en) | Class of compounds for treating ischemic brain damage and purpose thereof | |
| CN101011452A (en) | Plant extract with hypotensive effect and its preparing process and use | |
| CN103787949A (en) | Compound for protecting transplanted organs and application thereof | |
| CN103788066A (en) | Compound for protecting transplanted organs and application thereof | |
| CN103788065A (en) | Compound for protecting transplanted organs and application thereof | |
| CN103787967A (en) | Compound for protecting transplanted organs and application thereof | |
| CN115120611B (en) | NO donor micelle composition and preparation method and application thereof | |
| CN111840512B (en) | Composition for treating cartilage repair and/or osteoarthritis | |
| CN103845330A (en) | Compound for reducing intraocular pressure and application thereof | |
| CN103830255A (en) | Application of paeoniflorin in preparation of medicines for treating cerebrovascular diseases | |
| CN104918629B (en) | SP peptides or derivatives thereof are preparing the application in reducing the horizontal medicines of IL 13 | |
| CN111228323A (en) | Application of alcohol extract of pyrola in preparation of medicine for preventing and/or treating myocardial ischemic diseases | |
| CN101897929B (en) | Improved composition as well as preparation method and application thereof | |
| CN101317840B (en) | Nano-composition, preparing method and application thereof | |
| CN103800337A (en) | Compound for treating neurodegenerative diseases and application thereof | |
| Yu et al. | A multifunctional enzyme cascade catalytic nanoplatform for effective synergistic therapy of rheumatoid arthritis | |
| CN103877109B (en) | Application of Lactucoside B in the Preparation of Drugs for Preventing and Preventing Kidney Transplantation | |
| CN114288419B (en) | Preparation of a rifampicin nano drug delivery system and its application in the prevention and treatment of Parkinson's disease | |
| CN103804362A (en) | Compounds for treating diabetes and application thereof | |
| CN103845334A (en) | Compound for reducing intraocular pressure and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140514 |